Does perimenopause cause insulin resistance?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Partly, and the evidence is more mixed than most articles admit. The American Heart Association scientific statement reports that metabolic syndrome prevalence rises with menopause independently of ageing, while changes in insulin and glucose themselves appear more influenced by chronological ageing. Menopause shifts fat to the abdomen and worsens lipids, and that redistribution is the clearer link to insulin resistance.
Menopause contributes to insulin resistance, mostly through where fat goes rather than through a direct hormonal switch. The American Heart Association scientific statement on the menopause transition reports that the prevalence of metabolic syndrome increased with menopause independently of chronological ageing, while individual components such as insulin and glucose were more influenced by ageing itself. That distinction matters, because it means age and menopause are both in play and separating them is genuinely difficult.
The part that is well established
Visceral fat is the mechanism with the strongest support. The American Heart Association statement documents increases in total abdominal, subcutaneous and visceral fat across the transition after adjusting for age, alongside a sharp rise in LDL cholesterol and apolipoprotein B around the final period. Visceral fat is metabolically active and is closely linked to reduced insulin sensitivity. Lean mass is falling in the same window, and muscle is the largest site of glucose disposal in the body, so losing it lowers the capacity to clear glucose after meals.
The part that is contested
Whether estrogen loss itself causes insulin resistance, separate from body composition and ageing, remains debated. Observational cohorts disagree, and disentangling menopause from ageing requires long follow up through the transition. The claim that hormone therapy is a treatment for insulin resistance goes beyond the evidence. The Menopause Society does note that women who use hormone therapy have a lower risk of developing type 2 diabetes, but lower diabetes incidence in trials is not the same as an approved indication, and hormone therapy is not prescribed for metabolic reasons alone.
What to do about it
| Action | What it targets |
|---|---|
| Resistance training twice weekly or more | Preserves the muscle that clears glucose |
| Protein at each meal | Supports lean mass during the transition |
| Treating disrupted sleep and night sweats | Short sleep worsens insulin sensitivity |
| Annual HbA1c, fasting glucose and lipids with ApoB | Detects drift early rather than at diagnosis |
Ask for HbA1c, fasting glucose and a lipid panel including ApoB around the final period rather than waiting for symptoms, because the lipid shift in particular happens quickly. If fasting insulin is being measured, ask what threshold would change treatment before agreeing to the test. The intervention with the best evidence in this window is the least fashionable one: lifting weights and eating enough protein to keep the muscle you have.
The clinical detail
The 2020 American Heart Association scientific statement separates menopause related from age related metabolic change: metabolic syndrome prevalence rose with menopause independently of chronological ageing, whereas insulin and glucose changes were more influenced by ageing. Fat redistribution to visceral depots and the rise in LDL cholesterol and apolipoprotein B cluster tightly around the final menstrual period. HOMA-IR is calculated as fasting insulin in microunits per millilitre multiplied by fasting glucose in millimoles per litre, divided by 22.5, and it has no single validated cutoff for clinical decisions, which is why it supports a picture rather than defining a diagnosis.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. Circulation, American Heart Association. doi:10.1161/CIR.0000000000000912
- Hormone Therapy. The Menopause Society
- Menopause. Endocrine Society
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.